Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 431-434

  Kojima, Shunichi ^a   Shida, Mikio ^a   Yokoyama, Hiroyuki ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Atherosclerosis; C reactive protein; Interleukin 6; LDL apheresis

Indexed keywords

C REACTIVE PROTEIN; DEXTRAN SULFATE; HYPOCHOLESTEROLEMIC AGENT; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; STATIN;

ADSORPTION; ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT OUTCOME; VASCULAR DISEASE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLASMAPHERESIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0042316778     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00080.x     Document Type: Article

References (22)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
3. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
5. Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vas Biol 1998;18:1386-92.
6. Zhang YX, Cliff WJ, Schoefi GI, Higgins G. Coronary C-reactive protein distribution. Its relation to development of atherosclerosis. Atherosclerosis 1999;145:375-9.
7. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima; role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
8. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effects of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-9.
9. Mortensen RF, Osmand AP, Lint TF, Gewurz H. Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol 1976;117:774-81.
10. De Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982;156:230-42.
11. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1985;27:83-91.
12. Rowe IF, Soutar AK, Trayner IM et al. Rabbit and rat C-reactive protein bind apolipoprotein B-binding lipoproteins. J Exp Med 1984;159:604-16.
13. Jialal I, Stein D, Bailis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
14. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
15. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoproteins by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
16. Kojima S, Harada-Shiba M, Toyota Y et al. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185-90.
17. Kojima S, Harada-Shiba M, Nomura S et al. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991;37:644-8.
18. Ockene IS, Marthews CE, Rifai N, Ridker PM, Reed G, Stanck E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50.
19. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem 2001;47:426-30.
20. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
21. Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients under going HELP LDL apheresis. Atherosclerosis 2001;158:495-8.
22. Memoli B, Libetta C, Rampino T et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992;42:320-6.